An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

Trial Profile

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs Enclomifene (Primary)
  • Indications Hypogonadism
  • Focus Pharmacokinetics
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 11 Mar 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Oct 2014 Celerion is Clinical research organization. It is not a pharmaceutical company.
    • 28 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top